$RLYB · Rallybio Corp
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases.
More about this company
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Not currently held by tracked 13F filers — this page aggregates activist, insider, politician and research activity.
Beyond 13F — activists, insiders, politicians & research
| Filed | Form | Activist | % of class | Conviction | |
|---|
| 2026-05-06 | SCHEDULE 13D/A | 5AM Ventures V, L.P. | | Low | filing |
| 2026-03-03 | SCHEDULE 13D/A | TPG GP A, LLC | 7.2% | High | filing |
| 2026-02-27 | SCHEDULE 13D/A | 5AM Ventures V, L.P. | 5.5% | Med | filing |
| Filed | Insider | Role | Shares | Value | |
|---|
| 2026-05-15 | ADAR1 Capital Management, LLC | 10%-owner | 79,559 | $1,112,977 | Form 4 |
| 2026-05-13 | ADAR1 Capital Management, LLC | 10%-owner | 50,800 | $711,055 | Form 4 |
| 2026-05-06 | ADAR1 Capital Management, LLC | 10%-owner | 155,905 | $2,178,668 | Form 4 |